During the past three decades, the risk of dying from breast cancer in the United States has declined by nearly half, thanks to a combination of screening and early therapy as well as more treatments that are effective with fewer side effects, especial...
[56] Soleyman-Jahi S, Zendehdel K, Sadeghi F, et al. Inhibitory effects of aprotinin on survival and local invasion of human breast cancer cell lines. 2017 AACR Abstract 4. [57] Nunes M, Vrignaud P, Vacher S, et al. Evaluating patient-derived colorectal cancer xenografts as preclinical...
During the past three decades, the risk of dying from breast cancer in the United States has declined by nearly half, thanks to a combination of screening and early therapy as well as more treatments that are effective with fewer side effects, especially in the adjuvant setting. Therefore, it...
During the past three decades, the risk of dying from breast cancer in the United States has declined by nearly half, thanks to a combination of screening and early therapy as well as more treatments that are effective with fewer side effects, especially in the adjuvant setting. Therefore, it...
Combination therapy of a HER2 inhibitor and an AKT inhibitor, as well as other PI3K pathway inhibitors, could overcome the therapeutic limitations associated with single-agent anti-HER2 treatment in-mutant HER2+ breast cancer cell lines. Furthermore, expression of phosphorylated 4E-binding protein 1 ...
HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive casesHER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive casesTargeti...
the proliferation and survival of HER2-positive breast-cancer cell lines. However, a major obstacle remained to be overcome — the development of a "humanized" murine monoclonal antibody that could be safely and repeatedly administered to patients with HER2-positive breast cancer. Dr. Shephard led ...
题目为A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response。 本文对乳腺癌细胞系进行了单细胞分析,以研究肿瘤的异质性和药物反应。作者发现生物标志物的表达存在高度的异质性,并提供了一个框架来确定肿瘤在细胞系组成和药物反应方面的异质性。他们还将细胞系中大...
Biologics: Targets & Therapy Dovepress open access to scientific and medical research Open Access Full Text Article HER2 breast cancer therapies: a review review Conleth G Murphy Shanu Modi Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY,...
Cimino-Mathews A, Foote JB, Emens LA. Immun-targeting in breast cancer. Oncology (Williston Park). 2015;29(5):375-385. Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre. phase 1b ...